Golden, CO – According to filings with the U.S. Securities and Exchange Commission, BioIntelliSense is raising $25,000,000.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Mark Adolph played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About BioIntelliSense

The BioIntelliSense Data-as-a-Service (DaaS) platform and FDA-cleared BioSticker on-body sensor are bringing medical grade monitoring and management to the home for scalable remote care. The FDA-cleared BioSticker medical device is designed to be discreetly worn on the upper left chest for effortless remote data capture and a simplistic stick it on and forget it patient experience. The physician prescribed BioSticker is the first single-use medical device for up to 30 days of continuous vital sign monitoring.

To learn more about BioIntelliSense, visit http://biointellisense.com/

Contact:
Mark Adolph, Chief Financial Officer
303-578-2648

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved